Type 2 Diabetes

Type 2 diabetes, formerly called adult-onset or noninsulindependent diabetes, is the most common form of diabetes. People can develop type 2 diabetes at any age, even during childhood. This form of diabetes usually begins with insulin resistance, a condition in which fat, muscle, and liver cells do not use insulin properly. At first, the pancreas keeps up with the added demand by producing more insulin. In time, however, it loses the ability to secrete enough insulin in response to meals. People who are overweight and inactive are more likely to develop type 2 diabetes. Treatment includes taking diabetes medicines, making wise food choices, exercising regularly, controlling blood pressure and cholesterol, and taking aspirin daily—for some.

What is Type 2 Diabetes?

Type 2 diabetes is a common metabolic condition that develops when the body fails to produce enough insulin or when insulin fails to work properly, which is referred to as insulin resistance. Insulin is the hormone that stimulates cells to uptake glucose from the blood to use for energy.

Insulin Resistance Symptoms

Does the Keto Diet Increase the Risk of Diabetes?

Type 2 Diabetes Screening and Prevention

The Risks of Prediabetes

Living With Type 2 Diabetes

Type 2 Diabetes Symptoms

Insulin Resistance and Parkinson's Disease

Causes of Insulin Resistance

Is a Plant-Based Diet Good for Type 2 Diabetes?

Insulin Medication

What is Diabetes?

See more featured articles »

Type 2 Diabetes Treatment

Diabetes in Men versus Women

Insulin Resistance Diagnosis

What is Insulin Resistance?

Insulin Resistance Treatment

Insulin Resistance Pathophysiology

Type 2 Diabetes Diagnosis

Fibromyalgia and Diabetes

Are Low Carbohydrate Diets Good for Type 2 Diabetes?

Diabetes Mellitus Type 2 Pathophysiology

Vitamin D and Type 2 Diabetes

Latest Type 2 Diabetes News and Research

GLP-1 medications may lower risk of multiple substance use disorders

A new study led by researchers at The University of Texas at El Paso found that use of weight loss drugs like Ozempic and other GLP-1s is associated with a lower risk of developing alcohol, opioid, nicotine and cocaine use disorders.

21 Jun 2026

Synthetic gut communities reveal how diet rewires the microbiome

Synthetic microbial communities give researchers controlled models for testing how diet reshapes gut microbial ecology, metabolism, and host-relevant responses. The review highlights how SynComs can strengthen causal inference, improve intervention testing, and support future precision nutrition, while noting major challenges in stability, standardization, and ecological realism.

21 Jun 2026

Epigenetic drugs improve blood vessel health in obesity and diabetes

People with obesity and type 2 diabetes are at high risk of blood vessel damage. This risk depends not only on the genes a person carries, but also on how they are "read".

18 Jun 2026

PMOS rethink reframes a common hormone disorder as a whole-body disease

A new review reframes PCOS, now proposed as PMOS, as a systemic endocrine and metabolic disorder shaped by genetic, epigenetic, ovarian, metabolic, and neuroendocrine pathways. It highlights why inconsistent diagnosis and symptom-focused care have limited progress, while targeted therapies, biomarkers, machine learning, and organ-on-chip models may support more personalized treatment.

18 Jun 2026

Gut microbes may help explain why obesity and type 2 diabetes become harder to reverse

This review describes how gut microbial messengers, including SCFAs, microbiota-modified bile acids, neuroactive metabolites, and extracellular vesicles, may shape obesity and type 2 diabetes through the microbiota-gut-brain axis.

17 Jun 2026

Onion-loving gene linked to lower diabetes and blood pressure risk

Imagine if a doctor could look at your DNA and predict not just your disease risk, but also which foods you're drawn to – and whether those cravings are quietly protecting you.

17 Jun 2026

Study identifies top predictors for weight loss using tirzepatide

One of the largest real-world studies of people taking GLP-1 medications found women, those without pre-existing conditions such as type 2 diabetes and high blood pressure, and behavioral factors such as previously setting a weight goal were the best predictors of total weight loss, according to a study being presented Monday at ENDO 2026, the Endocrine Society's annual meeting in Chicago, Ill.

16 Jun 2026

Long daily naps increase liver disease risk in diabetic patients

People with type 2 diabetes who nap longer than 30 minutes every day, regardless of their sleep patterns at night, increase their risk of developing metabolic dysfunction-associated steatotic liver disease (MASLD), according to a study being presented Monday at ENDO 2026, the Endocrine Society's annual meeting in Chicago, Ill.

15 Jun 2026

Weight-loss surgery for obese teens found to be cost-effective over 10 years

Metabolic and bariatric surgery for teens with severe obesity was found to be cost-effective over 10 years, according to the new analysis from Ann & Robert H. Lurie Children's Hospital of Chicago published in JAMA Network Open.

15 Jun 2026

Synthetic cooling agents in e-cigarettes link to abnormal heartbeats

Synthetic cooling ingredients added to e-cigarettes caused abnormal heartbeats (arrhythmias) and increased cardiovascular risk measures in mice and lab-grown human heart cells, according to new independent research published today in Circulation: Arrhythmia and Electrophysiology, a peer-reviewed journal of the American Heart Association.

15 Jun 2026

American Heart Association launches platform for earlier heart failure risk identification

Nearly 7 million people in the United States are living with heart failure, and that number is expected to grow in the years ahead.

15 Jun 2026

The importance of ketones from a clinical and medical perspective

In this interview, News-Medical talks to Marcin Pacek, senior director of medical and scientific affairs in Europe for Nova Biomedical, about the importance of ketones in a medical and clinical setting.

From Nova Biomedical 15 Jun 2026

Blood-based indicator assesses organ age to predict disease risk

The candles on your birthday cake don't tell the whole story. As anyone who ever attended a high-school reunion can tell you, some people age faster than others.

15 Jun 2026

Study reveals frequent stop-and-start patterns with GLP-1 drugs

People prescribed GLP-1 medications are more likely to start-and-stop than most people assume, according to a study being presented Sunday at ENDO 2026, the Endocrine Society's annual meeting in Chicago, Ill.

14 Jun 2026

Testosterone benefits older men with T2D risk when combined with lifestyle changes

Testosterone treatment may improve body composition, glucose metabolism and sexual desire in some older men at high risk of type 2 diabetes (T2D), but the benefits require engagement in a lifestyle program, according to a study being presented Saturday at ENDO 2026, the Endocrine Society's annual meeting in Chicago, Ill.

14 Jun 2026

GLP-1 therapy associated with more dizziness and fainting

Northwestern Medicine scientists have identified a safety concern associated with GLP-1 drugs. Using health record data, the research team tracked more than 42,000 adults already taking at least two types of blood pressure medications.

14 Jun 2026

Scientists uncover protein-folding mechanism linked to diabetes progression

Origami masters turn simple sheets of paper into ornate sculptures. In the origami of life, our cells must fold proteins into specific three-dimensional shapes before they can carry out their biological jobs.

11 Jun 2026

Oral semaglutide improves blood sugar, weight, and liver markers in real-world diabetes care

A nationwide Finnish registry study of 7,249 GLP-1RA-naïve adults with type 2 diabetes found that once-daily oral semaglutide was associated with 12-month improvements in HbA1c, body weight, lipid markers, and ALT.

11 Jun 2026

Oral GLP-1 drug elecoglipron helps adults lose up to 11.8% body weight

Once-daily oral elecoglipron produced dose-dependent weight loss in adults with obesity or overweight without diabetes, with mean reductions reaching 10.5% at 26 weeks and 11.8% at 36 weeks in the highest-dose weekly-titration group. The phase 2 trial found no evidence of a weight-loss plateau by 36 weeks, while gastrointestinal adverse events were common but generally manageable.

11 Jun 2026

Low blood pressure shows strongest link to Alzheimer's disease

Numerous types of cardiovascular disease and CVD risk factors were linked to a higher risk of Alzheimer's disease, with low blood pressure showing the strongest connection, according to a new analysis published today in the Journal of the American Heart Association, an open access, peer-reviewed journal of the American Heart Association.

10 Jun 2026